Just a moment, the page is loading...

*EISAI-E7080-G000-205 Ph2

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
E7080-G000-205 Ph2
EU CTR 2010-019484-10
Metastatic Renal Cell Carcinoma
Phase 2
Sharing of clinical data is prevented for the following countries; Czech Republic.
November 2017